Sökning: "B-cell lymphoma"

Visar resultat 41 - 45 av 138 avhandlingar innehållade orden B-cell lymphoma.

1. 41. T Regulatory Cells – Friends or Foes?

   Författare :Camilla Lindqvist; Angelica Loskog; Thomas Tötterman; Vivianne Malmström; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Treg; T regulatory cell; FoxP3; CD25; CLL; B-cell lymphoma; Clinical immunology; Klinisk immunologi; Klinisk immunologi; Clinical Immunology;

   Sammanfattning : T regulatory cells (Tregs) have been extensively studied in patients with cancer or autoimmunity. These cells hamper the immune system’s ability to clear tumor cells in cancer patients. In autoimmune diseases, on the other hand, they are not able to restrain autoreactive immune responses. LÄS MER

3. 42. Molecular epidemiology approach : nested case-control studies in glioma and lymphoid malignancies

   Författare :Florentin Späth; Beatrice S. Melin; Carl Wibom; Ann Sofie Johansson; Ingvar Bergdahl; Ola Landgren; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Glioma; B cell lymphoma; multiple myeloma; risk; repeated samples; prospective longitudinal study; nested case-control study; circulating sEGFR and sERBB2; circulating immune markers and growth factors; marker disease association; disease progression; NSHDS; Janus; linear mixed modeling; epidemiologi; Epidemiology; Oncology; onkologi;

   Sammanfattning : BACKGROUND: Nested case-control studies aim to link molecular markers with a certain outcome. Repeated prediagnostic samples may improve the evaluation of marker-disease associations. However, data regarding the benefit of repeated samples in such studies are sparse. LÄS MER

4. 43. Prognostic signficance of tumor cell markers in diffuse large B-cell lymphoma with special emphasis on lymphoma localization

   Författare :Maysaa Abdulla; Rose-Marie Amini; Gunilla Enblad; Wolfram Klapper; Uppsala universitet; []
   Nyckelord :;

   Sammanfattning : Diffuse large B-cell lymphoma (DLBCL) is the most common type of high-grade B-cell lymphoma with different clinical, morphological, immunophenotypical, and molecular features. DLBCL is curable in 60-70% of patients when treated with standard immunochemotherapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). LÄS MER

5. 44. CAR T cells for Immunotherapy of Cancer

   Författare :Tina Sarén; Magnus Essand; Martin Pule; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Chimeric antigen receptor CAR -T cells; Cancer immunotherapy; NAP; Tonic signaling; T cell exhaustion; B cell lymphoma; clinical trial; glioblastoma;

   Sammanfattning : In recent years, immunotherapy has revolutionized cancer treatment by prolonging survival and even curing patients lacking other available therapies. Besides immune checkpoint inhibitors, one of the major advances is attributed to the success of chimeric antigen receptor (CAR)-T cell therapy in treating patients with B-cell malignancies. LÄS MER

7. 45. Internal dosimetry. Macroscopic, small-scale and microscopic perspectives

   Författare :Cecilia Hindorf; Lund Medicinsk strålningsfysik; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; radiobiologi; Nukleärmedicin; radiobiology; Nuclear medicine; B-cell lymphoma; Radioimmunotherapy; Radionuclide therapy; Internal dosimetry; Radiopharmaceutical technology; Radiofarmaceutisk teknik;

   Sammanfattning : Internal dosimetry deals with the assessment of absorbed dose for radionuclides distributed inside the body. The absorbed dose is in its turn used for correlation with the biological effect caused by the irradiation. LÄS MER